Regulus Therapeutics (NASDAQ:RGLS) Given “Buy” Rating at Canaccord Genuity Group

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating restated by stock analysts at Canaccord Genuity Group in a research report issued on Monday,Benzinga reports. They presently have a $28.00 price target on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Friday. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Regulus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Regulus Therapeutics Price Performance

RGLS traded down $0.03 on Monday, hitting $1.45. 24,007 shares of the stock were exchanged, compared to its average volume of 520,879. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $3.00. The business has a 50-day moving average of $1.28 and a two-hundred day moving average of $1.46. The firm has a market capitalization of $94.98 million, a price-to-earnings ratio of -1.36 and a beta of 1.42.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). During the same period last year, the company posted ($0.40) EPS. Equities research analysts expect that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Insider Activity

In other Regulus Therapeutics news, CFO Crispina Calsada sold 38,716 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,782.16. Following the completion of the sale, the chief financial officer now owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. This represents a 43.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,569.22. Following the sale, the vice president now directly owns 54,634 shares of the company’s stock, valued at $68,838.84. This represents a 41.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 223,998 shares of company stock valued at $282,237 over the last quarter. 4.35% of the stock is owned by company insiders.

Institutional Trading of Regulus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Regulus Therapeutics during the 3rd quarter valued at approximately $46,000. PEAK6 LLC bought a new position in shares of Regulus Therapeutics during the 4th quarter worth approximately $95,000. Velan Capital Investment Management LP bought a new position in shares of Regulus Therapeutics during the 4th quarter worth approximately $111,000. JPMorgan Chase & Co. boosted its holdings in shares of Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 52,059 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 62,549 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.